ATE295837T1 - Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen - Google Patents

Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen

Info

Publication number
ATE295837T1
ATE295837T1 AT02760975T AT02760975T ATE295837T1 AT E295837 T1 ATE295837 T1 AT E295837T1 AT 02760975 T AT02760975 T AT 02760975T AT 02760975 T AT02760975 T AT 02760975T AT E295837 T1 ATE295837 T1 AT E295837T1
Authority
AT
Austria
Prior art keywords
sup
treatment
pain
antagonists
type calcium
Prior art date
Application number
AT02760975T
Other languages
English (en)
Inventor
Amico Derin D
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE295837T1 publication Critical patent/ATE295837T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • C07D215/44Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
AT02760975T 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen ATE295837T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102858A SE0102858D0 (sv) 2001-08-27 2001-08-27 N-type calcium channel antagonists for the treatment of pain
PCT/SE2002/001521 WO2003018561A1 (en) 2001-08-27 2002-08-23 N-type calcium channel antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
ATE295837T1 true ATE295837T1 (de) 2005-06-15

Family

ID=20285150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760975T ATE295837T1 (de) 2001-08-27 2002-08-23 Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen

Country Status (7)

Country Link
US (1) US7153865B2 (de)
EP (1) EP1430030B1 (de)
JP (1) JP2005508894A (de)
AT (1) ATE295837T1 (de)
DE (1) DE60204232T2 (de)
SE (1) SE0102858D0 (de)
WO (1) WO2003018561A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2004080444A2 (en) * 2003-03-10 2004-09-23 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
US7223754B2 (en) 2003-03-10 2007-05-29 Dynogen Pharmaceuticals, Inc. Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders
WO2005000285A2 (en) * 2003-06-13 2005-01-06 Dynogen Pharmaceuticals, Inc. METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS
WO2006058201A2 (en) * 2004-11-23 2006-06-01 Reddy Us Therapeutics, Inc. Heterocyclic and bicyclic compounds, compositions and methods
EP1963280B1 (de) 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylaminoderivate als calcium- und/oder natrium-kanalmodulatoren
CA2689561C (en) 2007-06-15 2015-11-17 Newron Pharmaceuticals S.P.A. Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators
EP2496234A1 (de) 2009-11-07 2012-09-12 Merck Patent GmbH Heteroarylaminochinoline als tgf-beta-rezeptorkinase-inhibitoren
PT2723710T (pt) 2011-06-27 2016-11-14 Newron Pharm Spa Derivados fluorados de arilalquilaminocarboxamida
WO2014120995A2 (en) * 2013-02-01 2014-08-07 Wellstat Therapeutics Corporation Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
EA201591746A1 (ru) 2013-03-14 2016-08-31 КОНВЕРДЖЕН ЭлЭлСи Способы и композиции для ингибирования бромодомен-содержащих белков
JP6882289B2 (ja) 2015-11-25 2021-06-02 コンバージーン・リミテッド・ライアビリティ・カンパニーConvergene Llc 二環式betブロモドメイン阻害剤及びその使用
US10889566B2 (en) * 2017-08-29 2021-01-12 Chulabhorn Foundation Derivatives and composition of quinoline and naphthyridine
WO2020219168A1 (en) 2019-04-24 2020-10-29 Convergene, Llc Small molecule bromodomain inhibitors and uses thereof
WO2023081800A1 (en) * 2021-11-05 2023-05-11 The Regents Of The University Of California Alpha-2a adrenergic receptor modulators and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1573186A (en) * 1977-09-14 1980-08-20 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
WO2000064877A1 (en) 1999-04-26 2000-11-02 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands

Also Published As

Publication number Publication date
JP2005508894A (ja) 2005-04-07
EP1430030B1 (de) 2005-05-18
WO2003018561A1 (en) 2003-03-06
SE0102858D0 (sv) 2001-08-27
US7153865B2 (en) 2006-12-26
US20050131020A1 (en) 2005-06-16
DE60204232T2 (de) 2006-01-26
DE60204232D1 (de) 2005-06-23
EP1430030A1 (de) 2004-06-23

Similar Documents

Publication Publication Date Title
ATE323693T1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DE60204232D1 (de) Antagonisten für calciumkanäle vom n-typ zur behandlung von schmerzen
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
EA200401169A1 (ru) Аминометилзамещенные тетрациклиновые соединения
BRPI0408782A (pt) inibidores cìclicos da proteìna tirosina cinase
DE59807405D1 (de) Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende mittel und verfahren zu ihrer herstellung
DE60321929D1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BR0009721A (pt) Inibidores de tirosina quinase de proteìna cìclica
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ATE284690T1 (de) Antithrombotische diamine
ES2190803T3 (es) Iminas ciclicas como pesticidas.
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE69905170T2 (de) Thiazolopyrimidinderivate
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
YU13301A (sh) Muskarinski agonisti i antagonisti
SE0004054D0 (sv) N-type calcium channel antagonists for the treatment of pain
TR199700834T1 (xx) 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
SE0003476D0 (sv) Compounds
SE9802937D0 (sv) Novel compounds
DE60326069D1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
BR0311386A (pt) Furancarboxamidas
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60137534D1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
DE50311756D1 (de) Mikrobizide oxathiincarboxamide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties